Paper Details

  1. Home
  2. Paper Details

No evidence of large genetic effects on steroid response in asthma patients.

Author: GhoshSoumitra, HoskingLouise, MostellerMichael, MurphyKay, NelsonMatthew, ShenJudong, SongKijoung

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This pharmacogenetic study of 2672 ICS-treated patients with asthma did not find any evidence to support previously reported associations between candidate genetic variants and ICS response. The study analyzed over 9.8 million common genetic variants.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Inhaled corticosteroids (ICSs) are considered the most effective anti-inflammatory therapy for asthma control and management; however, there is substantial treatment response variability. OBJECTIVE: We sought to identify genetic markers of ICS response by conducting the largest pharmaco...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jaci.2016.05.032

データ提供：米国国立医学図書館（NLM）

The Desert of Asthma Treatment: Searching for Genetic Clues

Inhaled corticosteroids (ICSs) are widely used to manage asthma, but treatment response can vary significantly among patients. This study delves into the genetic basis of ICS response in patients with asthma, aiming to identify genetic markers that could predict treatment effectiveness. The researchers conducted a large pharmacogenetic investigation involving over 2,600 patients receiving ICS treatment. Despite their extensive analysis, the study found no evidence of strong genetic effects on ICS response, suggesting that other factors may play a more prominent role.

A Shifting Sandscape in the Desert of Asthma Research

The study's findings suggest that the search for genetic predictors of ICS response may be more complex than initially anticipated. It highlights the importance of considering a multifaceted approach, exploring other factors that may contribute to treatment variability, such as environmental factors, lifestyle choices, and individual patient characteristics. It's like navigating a shifting sandscape in the desert of asthma research, requiring flexibility and adaptability to uncover the underlying mechanisms of treatment response.

Navigating the Desert of Asthma Management: A Personalized Approach

This study emphasizes the importance of a personalized approach to asthma management. While genetic factors may play a role, it's crucial to consider a wide range of factors to optimize treatment effectiveness. It's like choosing the most suitable path through the desert of asthma management, taking into account individual needs and preferences to achieve optimal outcomes.

Dr.Camel's Conclusion

This study sheds light on the complexity of ICS response in asthma, suggesting that genetic factors alone may not fully explain treatment variability. It's like navigating a shifting sandscape in the desert of asthma research, requiring a multifaceted approach to uncover the underlying mechanisms of treatment response and provide personalized care for patients.

Date :
  1. Date Completed 2017-07-21
  2. Date Revised 2017-07-21
Further Info :

Pubmed ID

27523435

DOI: Digital Object Identifier

10.1016/j.jaci.2016.05.032

Related Literature

Article Analysis
・Effective treatment of asthma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.